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Abstract
Background: Aim of the study was to determine the clinical efficacy of a new antiseptic liquid soap
(Stellisept® scrub), based on the combination of undecylenamidopropyltrimonium methosulphate
(4%) and phenoxyethanol (2%), for eradication of MRSA among colonized patients who do not
receive antibiotic therapy.
Methods: Over two years 50 MRSA patients in 6 hospitals were observed. Treatment was defined
as the daily application of Stellisept scrub for the antiseptic body and hair wash (at least 60 s) in
combination with nasal mupirocin. A treatment cycle was a minimum of 5 days treatment.
Screening was carried out at least 48 h after the treatment cycle was finished, with 24 h between
each of the requested three or more samplings, which included the nasopharynx, groin, axilla,
perineum and other MRSA-positive skin areas.
Results:  Fifteen cases were retrospectively excluded (lack of outcome documentation,
concomitant antibiotic therapy, open wounds). All 35 patients had colonization with MRSA before
antiseptic treatment on the skin, in the groin (80%), the axilla (25.7%), the perineum (20%) or other
skin areas (14.3%). Colonization at more than one skin sites was found in 34.3%. Nasal colonization
was found in 21 of 28 patients (75%), 7 patients were without nasal screening prior to the antiseptic
treatment. After one treatment cycle MRSA was eradicated in 25 patients (71.4%), after a second
cycle the total eradication rate was 91.4%, after a third cycle the rate increased to 94.2%. No
patient discontinued the antiseptic treatment due to dermal intolerance of the product.
Conclusions: Progressive eradication of MRSA carriage was observed with the antiseptic soap and
mupirocin. The eradication rate was not biased by concomitant antibiotic treatment, screening
during treatment or lack of evidence for colonization in contrast to other studies with other
preparations.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) contin-
ues to be a global problem in infection control. For many
years it has been a major cause for nosocomial infections
in many countries [1,2]. The proportion of methicillin
resistance among clinical isolates of S. aureus is still
increasing. In southern European countries, the propor-
tion may be as high as 55% [3,4]. MRSA now even
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becomes an increasing problem in the community [5,6].
Transmission of MRSA in community has been shown to
be as high as 60% [7]. Family members who are living
with MRSA carriers are in danger of MRSA transmission
[7]. Dermal colonization with MRSA may be persistent,
especially in the groin [8]. That is why attempts are often
undertaken to treat colonized MRSA patients [9]. Antibi-
otics were shown to be effective in uncontrolled and con-
trolled trials with eradication rates between 53% and 85%
[10-12]. But antibiotics are considered to be inappropriate
for patients who are only colonized and not infected with
MRSA [13]. One reason is their potential to cause adverse
effects, especially allergy, which can not be justified for
patients who do not have an infection. More important is
the risk of emergence of vancomycin-resistance in S.
aureus [14]. Topical antiseptic measures, however, are nor-
mally employed [15]. The nasal cavity is usually treated
with mupirocin or with tolerable antiseptics [16]. Dermal
colonization is eradicated with antiseptic liquid soaps
[13] Only few studies have addressed the question of
MRSA eradication among colonized patients with liquid
soaps in combination with nasal treatment. All of them
are uncontrolled trials and most of them have different
types of biases.
Aim of our study was to determine the efficacy of the anti-
septic soap Stellisept scrub in combination with mupi-
rocin for eradication of MRSA among colonized patients
with evidence of dermal colonization (no selection bias),
without concomitant antibiotic therapy (no treatment
bias) and with regular screening investigations (no out-
come bias).
Methods
Study design
An open clinical trial was chosen as a study design.
Determination of MRSA carriage
The MRSA carrier status was determined before and after
treatment of the patients. Swabs were taken at least from
the following body sites: nasopharynx, axilla, groin and
perineum. Any patient with at least one MRSA positive
skin site was regarded as a patient with evidence for der-
mal colonization irrespective of the nasal colonization
status.
All swabs were processed on the same day. Briefly, swabs
were plated directly on blood agar, oxacillin resistance
screening agar base (Oxoid, UK), and dextrose broth for
enrichment. After incubation of plates and broth at 37°C
for 18 to 24 h, colonies resembling S. aureus were identi-
fied and tested for oxacillin resistance. This was done in
two steps: disk diffusion with a 5 µg oxacillin disk on
Mueller-Hinton agar (incubation at 30°C for 18 – 24 h)
and agar screening on Mueller-Hinton agar supplemented
with 6 mg/ml oxacillin and 4% saline (Oxa Screen Test
Agar, bioMérieux, France; incubation at 35°C for 24 h).
Isolates growing within 14 mm around the oxacillin disk
and growing on the MRSA screening plates were regarded
as oxacillin resistant.
Treatment of patients
Definition of treatment and treatment cycle: Treatment
was defined as the daily application of Stellisept scrub for
the antiseptic body and hair wash (at least 60 s) in combi-
nation with nasal mupirocin. A treatment cycle was
defined as a minimum of 5 days treatment.
Treatment of the nasal cavity
The nasal cavity was treated with mupirocin which was
applied twice per day as recommended by the manufac-
turer (Turixin®, GlaxoSmithKline, Munich, Germany).
Treatment of the skin
The skin and hair was treated once a day with the antisep-
tic liquid soap (Stellisept scrub, Bode Chemie GmbH &
Co., Hamburg, Germany) which is based on two active
ingredients: 4% (w/w) undecylenamidopropyltrimonium
methosulphate and 2% (w/w) phenoxyethanol. The min-
imum duration of antiseptic skin treatment was 60 s. This
application time is derived from in vitro data on the activ-
ity of the product against various epidemic MRSA strains
and various clinical MRSA isolates [17].
For body washing the skin was moistened with tap water
and the liquid soap applied without dilution. Mobile
patients washed themselves under supervision of a health-
care worker. Immobile patients were washed by health-
care workers. After the 60 s application residual soap had
to be rinsed or washed off with tap water. Linen and
clothes were changed during the antiseptic treatment and
the surrounding surfaces treated with a surface disinfect-
ant [13].
Patient selection and data
Six hospitals participated in the study. The local infection
control nurse of a hospital was responsible for data collec-
tion. Patients were included
• if there was evidence for dermal colonization with
MRSA irrespective of the colonized body site (minimum
screening of axilla, groin and perineum) and
• if they did not receive antibiotics at the beginning of the
treatment and
• if they had no signs of a clinical infection and
• if compliance with the treatment could be expected for
the anticipated duration of hospital stay.Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/9
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Patients were excluded
• if antibiotics were given during the treatment or during
the surveillance culture interval or
• antiseptic treatment was initiated for treatment of colo-
nized or infected wounds and
• if patients were discharged before screening cultures
could be obtained after treatment.
The following data were collected for each patient: gender,
hospital, MRSA positive body sites before and after the
antiseptic treatment (nasopharynx, axilla, groin, peri-
neum, other body sites) and additional information if rel-
evant for the outcome assessment. The microbiological
method in each hospital for identification of MRSA from
initial and follow-up swabs was not evaluated for its sen-
sitivity and specificity since it has become routine in Ger-
man laboratories.
Post treatment screening
Post treatment screening was done according to the Ger-
man recommendation on MRSA patients issued by the
Robert-Koch Institut [13]. A minimum wash-out period
of 48 h was required between the last treatment and the
first set of screening swabs. Screening swabs had to be
taken for three consecutive days and at least from the fol-
lowing sampling sites: nasopharynx, axilla, groin and
perineum. Additional body sites were included if they
were found to be MRSA positive before antiseptic
treatment.
Results
Fifty patients were treated between 2001 and 2002 in the
6 hospitals, mainly in surgery, internal medicine, inten-
sive care or other departments such as gynecology (n = 2),
neurology (n = 2), urology (n = 1) or dermatology (n = 1;
Table 1). Four of the 50 patients were discharged early
resulting in a lack of information on the outcome (coloni-
zation with MRSA after antiseptic treatment). Eight
patients received concomitant systemic antibiotic therapy
initiated after inclusion in the study. Three patients had a
colonized or infected wound which was treated during the
study. All of them were excluded resulting in a total of 35
cases with proven dermal MRSA colonization and without
concomitant systemic antibiotic therapy.
21 of the 35 patients were male (60%), the mean age was
69.1 years (minimum 27 years, maximum 91 years).
Nasal colonization was found in 21 of 28 patients (75%),
7 patients were without nasal screening prior to the anti-
septic treatment. Dermal colonization was documented
mainly in the groin (80%), followed by axilla (25.7%),
perineum (20%), forehead (5.7%), umbilicus (5.7%) and
upper leg (2.9%; Table 2). Multiple colonization of the
skin was found in 34.3% of the patients.
After one cycle of antiseptic body wash and concomitant
nasal antisepsis with mupirocin, 25 of the 35 patients
were found to be MRSA free (71.4%; Table 2). The mean
duration of treatment was 6.7 ± 2.5 days. Successful erad-
ication of MRSA was confirmed with three negative con-
secutive series of swabs in 16 patients (64%). Two
consecutive series of swabs were negative in five patients
(20%) and one series of swabs was negative in four
patients (16%) which was explained by early discharge of
the patient. Treatment failures after the first cycle were due
to persistent colonization of the same skin area (5 of 10),
colonization of another skin area (4 of 10) and persistent
colonization of the nasopharynx (1 of 10). Of the remain-
ing 10 patients, two were not treated any further due to
discharge and 8 underwent a second treatment cycle with
seven of them being MRSA negative afterwards (total of
91.4% being MRSA negative). The mean duration of treat-
ment in the second cycle was 6.4 ± 2.1 days. In order to
confirm successful eradication of MRSA after the second
cycle, three consecutive series of swabs were negative in six
patients (85.7%) and two consecutive series of swabs were
negative in one patient (14.3%). The one patient
remained colonized on the same skin area without nasal
carriage and underwent a third treatment cycle resulting in
dermal MRSA eradication (total of 94.2% being MRSA
negative; Table 2). Three series of consecutive swabs were
negative to confirm successful eradication of MRSA.
Table 1: Number of patients per hospital and the type of unit of all included patients.
Hospital Internal medicine Surgery Intensive care unit Other departments All departments
1 04419
2 6501 1 2
3 22004
4 43018
5 01135
6 6510 1 1
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No patient had to discontinue the antiseptic body wash
due to dermal intolerance or uncomfortable perception of
the product.
Discussion
Although eradication of MRSA from colonized patients is
regarded as a key element in prevention of transmission in
a hospital, so far only few studies have addressed the clin-
ical efficacy of antiseptic soaps in combination with a
nasal antiseptic for that purpose. No study was found with
a positive or negative control for the antiseptic skin treat-
ment, only one study was found with a negative control
for nasal mupirocin (Table 3). In addition, most of the
uncontrolled trials contain substantial biases which limit
or even diminish the value of them.
In our study, we found an eradication rate after one treat-
ment cycle of 71.4% which is comparable to antibiotic
treatment [10,18]. After two treatment cycles, the rate was
91.4% and came up to 94.2% after a third treatment cycle.
With no other antiseptic soap we were able to find com-
parable data which are not confounded by a lack of evi-
dence for initial MRSA colonization, concomitant
antibiotic therapy or screening cultures during antiseptic
treatment.
One limitation of our study is the lack of a control. We can
not exclude that washing with plain soap and water or
doing nothing would not have had a similar effect regard-
ing the eradication of MRSA, although it is very unlikely
based the persistence of MRSA colonization in the groin
[8]. It would have been much more interesting to compare
Stellisept scrub with either a non-medicated soap (nega-
tive control) or another antiseptic soap (e.g. based on
chlorhexidine). But the use of non-medicated liquid soap
would have been acting against the German recommen-
dation for MRSA patients (antiseptic soaps or liquid prep-
arations should be used for treatment of the skin) [13].
The use of medicated soap, however, would have been an
interesting option, ideally in a double-blind randomized
design. But chlorhexidine as the most common active
agent for this type of treatment has been described in
recent studies with artificial contamination of fingers with
MRSA to have no advantage compared with non-medi-
cated liquid soap [19,20]. It was therefore not considered
to be suitable as a positive control [21]. That is why an
open uncontrolled design was chosen.
Another limitation is the rather short follow-up of 5 days
after termination of the treatment (2 days wash-out and 3
days screening cultures). Most patients stayed as long in
their hospital as it was necessary to complete the screening
cultures. The main reason for even shorter follow-up is
discharge of the patient from a hospital. Continuation of
hospital stay with the only aim to complete screening cul-
tures was not possible in our study. Follow-up was
unknown in some studies [22,23], shorter in others [24]
or longer [10,18], but in some studies not for all patients
[8,25].
Treatment failures after the first cycle were mainly
observed at the same or another skin site. The surround-
ing may also contribute to re-colonization of a patient. It
was shown in one of our cases to originate from an electric
shaver which was not disinfected at all. MRSA may survive
on inanimate surfaces and cotton for more than 90 days
[26]. Even making the bed leads to a large increase of
MRSA in the air for 15 minutes [27]. Careful disinfection
of these possible sources and changing linen after the anti-
septic treatment is therefore crucial to ensure prevention
of re-colonization as recommended in the German guide-
line on MRSA patients [13].
Identification of MRSA was not carried out for all screen-
ing swabs in one laboratory but with the same test
method. Differences in the sensitivity and specificity have
been described [28-30] which may have an impact on the
identification of a MRSA patient. But it is unlikely to have
Table 2: Frequency of MRSA detection at different body sites among 35 patients undergoing antiseptic body wash and nasal antiseptic 
therapy for eradication of MRSA; colonization of multiple skin sites possible.
Localisation of MRSA 
colonization
Before treatment (n = 35) After treatment cycle 1 (n 
= 35)
After treatment cycle 2 (n 
= 8)
After treatment cycle 3 (n 
= 1)
Nasopharynx 21 1 0 0
Any skin site 35 7 1 0
▪ G r o i n 2 8 510
▪ Axilla 9310
▪ P e r i n e u m7210
▪ F o r e h e a d2100
▪ U m b i l i c u s2000
▪ U p p e r  l e g1000Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/9
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an impact on the result of the antiseptic treatment because
the method would have been the same before and after
treatment of the same patient. That is why it was justified
not to carry out the identification of MRSA in one specific
laboratory especially because recent data indicate that
determination of phenotypic resistance may largely
underestimate the genotypic resistance in MRSA [31].
Another finding is the good dermal tolerance of the anti-
septic soap. All 35 patients tolerated repetitive use of the
preparation very well, even more than one treatment
cycle. Another preparation (Octenisept) has been
described to lead to skin redness in 4 of 28 patients result-
ing in termination of the treatment [25]. The excellent
dermal tolerance of Stellisept scrub on intact and scarified
skin has been described before [32].
Conclusions
Stellisept scrub in combination with nasal mupirocin was
found to effectively and progressively eradicate MRSA
from colonized patients. Antiseptic treatment may have to
be repeated.
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